Molbio Diagnostics, a prominent player in the diagnostics sector, has fixed the final allotment date for its initial public offering. On Thursday, 13 August, the company’s registrar, Kfin Technologies Ltd., will publish the allotment results. Shares will be listed on the National Stock Exchange and Bombay Stock Exchange on Monday, 17 August.
The announcement follows a sharp rise in the grey‑market price (GMP) to ₹963, a 19.33 % premium over the IPO price of ₹807. With a subscription ratio of 70.26‑fold, the offering has attracted strong demand from both retail and institutional investors. Those who were not allotted will receive refunds starting 14 August, while allotted shares will be credited to demat accounts the same day.
What You Need To Know
1. Allotment date and verification process
Allotment results will be released on 13 August by Kfin Technologies, the registrar handling the IPO. Investors who applied can confirm whether they have received shares by logging into the Kfin portal, entering their PAN, demat account number or application number, and submitting the required details. The portal will display the exact number of shares allotted, if any. Those who did not receive shares will see a zero allotment and will be eligible for a refund.
For those who do not appear on the Kfin list, the company has already scheduled the refund process to begin on Friday, 14 August. Refunds will be processed through the same demat account used for the application, ensuring a seamless return of the investment to the applicant’s account.
2. Grey‑market performance and expected listing price
Over the past ten trading sessions, the GMP for the Molbio Diagnostics shares has trended upward, reflecting investor confidence. The latest GMP stands at ₹963, calculated by adding a 19.33 % premium to the IPO price. This figure is derived from the upper end of the price band and the current grey‑market premium.
Analysts note that the GMP has fluctuated between ₹0.00 and ₹220 in recent days, but the recent jump suggests a robust listing. The company’s estimated listing price of ₹963 is therefore a realistic target for the opening trade, though it remains subject to market volatility on the first day.
3. Subscription ratio and investor demand
The Molbio Diagnostics IPO attracted a subscription ratio of 70.26‑fold, meaning that for every share issued, 70.26 applications were received. This level of demand is considered high in the current market environment, where many offerings are only 2‑3 times oversubscribed.
Such a strong subscription indicates that the company’s valuation and business prospects are well‑received by the market. It also suggests that a large portion of the issue will be allotted, though the exact distribution between retail and institutional investors will be disclosed only after the allotment announcement.
4. Refund procedure and demat crediting
Applicants who do not receive any shares will be refunded on 14 August. The refund will be processed through the same demat account used for the IPO application, ensuring that the money is returned to the investor’s existing holdings without the need for additional paperwork.
Allotted investors will see their shares credited to their demat accounts on the same day, 13 August. The process is automated by Kfin Technologies, which updates the demat records once the allotment list is finalized.
5. Listing date and market debut
Molbio Diagnostics plans to list its shares on Monday, 17 August, on both the NSE and BSE. The listing will provide liquidity to shareholders and allow the market to price the company’s shares based on real‑time trading activity.
Investors should monitor the opening trade closely, as the first day can be volatile. The company’s performance will be judged against the estimated listing price and the GMP, with analysts comparing the opening price to the ₹963 target.
The Wider Picture
The Molbio Diagnostics IPO comes at a time when the Indian equity market is experiencing a resurgence of investor appetite. After a period of subdued activity, several high‑profile listings have begun to generate significant demand, reflected in high subscription ratios and elevated GMPs.
Regulatory bodies, including the Securities and Exchange Board of India (SEBI), have maintained a supportive stance towards IPOs, ensuring that companies can raise capital efficiently. The success of Molbio Diagnostics will likely reinforce confidence in the diagnostics sector, which has seen increased demand amid ongoing health challenges.
For investors, the key takeaway is that the company’s strong subscription and rising GMP suggest a positive market reception. However, the actual performance on the first day will depend on broader market conditions, liquidity, and investor sentiment.
In Short
Allotment results to be announced on 13 August by Kfin Technologies.
Grey‑market price stands at ₹963, a 19.33 % premium over the IPO price.
Subscription ratio of 70.26‑fold indicates high demand.
Refunds for non‑allotted applicants begin 14 August.
Listing on NSE and BSE scheduled for 17 August.
This article is based on reporting published by livemint.
